The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2
Semaglutide treatment for 24 weeks resulted in a clinically meaningful reduction in albuminuria in patients with overweight/obesity and non-diabetic CKD
DPP-4 was present throughout neural and muscular tissues of jejunum
Anatomopathological examination is nonspecific and aims to exclude other tumor diagnoses, with heterogeneous microscopy findings of a high mitotic index, nuclear atypia, necrosis, and hemorrhage being common
Moreover, fasting hyperglycaemia was responsible for 2.3 million cardiovascular deaths worldwide in 2021 [2]
Regular eye examinations are recommended for patients with existing diabetic eye disease during Semaglutide therapy